aTYR PHARMA (ATYR) Retained Earnings (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Retained Earnings came in at -$617.0 million in Q1 2026, down 934748.48% YoY from N/an in Q1 2025, and down 191.6% on a QoQ basis from $673.6 million in Q4 2025.
aTYR PHARMA (ATYR) Retained Earnings (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Retained Earnings data on file, last reported at -$617.0 million in Q1 2026.
- Quarterly Retained Earnings fell 934748.48% year-over-year to -$617.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$617.0 million (down 934748.48% YoY) and the FY2025 annual result came in at $673.6 million, up 1683985.0% from the prior year.
- Retained Earnings retreated to -$617.0 million in Q1 2026, from $673.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $673.6 million in Q4 2025 to a low of -$617.0 million in Q1 2026.
- A 5-year average of -$29.5 million and a median of -$66000.0 in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings surged 1683985.0% — and 2026, when it tumbled 934748.48%.
- Tracing ATYR's Retained Earnings over 5 years: stood at -$417.6 million in 2022, then jumped by 233.78% to $558.7 million in 2023, then slumped by 100.01% to -$40000.0 in 2024, then surged by 1683985.0% to $673.6 million in 2025, then slumped by 191.6% to -$617.0 million in 2026.
- The last three Retained Earnings figures came in at -$617.0 million (Q1 2026), $673.6 million (Q4 2025), and -$1000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 676.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 676.02 Mn |
| Mar 31, 2026 | -617.00 Mn |
| Dec 31, 2025 | 673.55 Mn |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 641.28 Mn |
| Mar 31, 2025 | -66,000.00 |
| Dec 31, 2024 | -40,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | -499.80 Mn |
| Mar 31, 2024 | -483.51 Mn |
| Dec 31, 2023 | 558.69 Mn |
| Sep 30, 2023 | -453.26 Mn |
| Jun 30, 2023 | -441.92 Mn |
| Mar 31, 2023 | -429.60 Mn |
| Dec 31, 2022 | -417.63 Mn |
| Sep 30, 2022 | -669,000.00 |
| Jun 30, 2022 | 484.29 Mn |
| Mar 31, 2022 | 483.73 Mn |
| Dec 31, 2021 | -263,000.00 |
| Sep 30, 2021 | 481.39 Mn |